2008 in cancer

FDA · US: 26 records / 19 drugsEMA · EU: 7 records / 6 drugsHealth Canada · CA: 7 records / 7 drugs

• Dec 24, 2008Degarelix FDA · US original application approved Malignant Prostate NeoplasmFIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients…openfda
• Dec 15, 2008Plerixafor FDA · US original application approved Multiple MyelomaMozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent…openfda
• Mar 20, 2008Bendamustine FDA · US original application approved Indolent B-Cell Non-Hodgkin LymphomaIndolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.openfda
• Mar 20, 2008Bendamustine FDA · US original application approved Chronic Lymphocytic LeukemiaChronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.openfda
• Oct 20, 2008Metformin FDA · US original application approved cancer not stated in this recordRIOMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2…openfda
• Oct 7, 2008Histamine EMA · EU centralised approved Acute Myeloid LeukemiaCeplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2).…ema
• Jun 10, 2008Lapatinib EMA · EU centralised approved Malignant Breast NeoplasmTyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2): in combination with capecitabine for patients…ema
• Apr 16, 2008Thalidomide EMA · EU centralised approved Multiple MyelomaThalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or…ema
• Dec 31, 2008Celecoxib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-12-31 (see label)openfda
• Dec 19, 2008Zoledronic Acid FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-12-19 (see label)openfda
• Dec 19, 2008Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-12-19 (see label)openfda
• Dec 19, 2008Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-12-19 (see label)openfda
• Dec 17, 2008Azacitidine EMA · EU centralised accelerated approved cancer not stated in this recordVidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:  intermediate 2 and…ema
• Oct 31, 2008Irinotecan Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as IRINOTECAN FOR INJECTION (DIN 02312409) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see…health-canada-dpd
• Oct 28, 2008Cetuximab Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ERBITUX (DIN 02271249) under ATC L01FE01 CETUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Sep 30, 2008Nilotinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TASIGNA (DIN 02315874) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Sep 26, 2008Pemetrexed FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-09-26 (see label)openfda
• Sep 26, 2008Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-09-26 (see label)openfda
• Sep 26, 2008Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-09-26 (see label)openfda
• Sep 15, 2008Filgrastim EMA · EU centralised approved cancer not stated in this recordTevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established…ema
• Sep 15, 2008Filgrastim EMA · EU centralised approved cancer not stated in this recordRatiograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established…ema
• Sep 8, 2008Porfimer FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-09-08 (see label)openfda
• Aug 20, 2008Azacitidine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-08-20 (see label)openfda
• Jul 9, 2008Bicalutamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PRO-BICALUTAMIDE (DIN 02311038) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Jun 30, 2008Verteporfin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-06-30 (see label)openfda
• Jun 23, 2008Panitumumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-06-23 (see label)openfda
• Jun 20, 2008Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-06-20 (see label)openfda
• Jun 10, 2008Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-06-10 (see label)openfda
• Jun 3, 2008Zoledronic Acid FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-06-03 (see label)openfda
• May 27, 2008Panitumumab Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as VECTIBIX (DIN 02308487) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• May 22, 2008Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-05-22 (see label)openfda
• May 22, 2008Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-05-22 (see label)openfda
• Feb 22, 2008Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-02-22 (see label)openfda
• Jan 25, 2008Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-01-25 (see label)openfda
• Jan 18, 2008Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-01-18 (see label)openfda
• Jan 17, 2008Nelarabine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ATRIANCE (DIN 02299925) under ATC L01BB07 NELARABINE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jan 14, 2008Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-01-14 (see label)openfda
• Jan 14, 2008Sirolimus FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2008-01-14 (see label)openfda
• Jan 11, 2008Temsirolimus Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TORISEL (DIN 02304104) under ATC L01EG01 TEMSIROLIMUS. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jan 11, 2008Paclitaxel EMA · EU centralised approved cancer not stated in this recordAbraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease…ema

RegulatoryAll 2008 records with filters →

Studies

3,865

Interventional

3,284

Phase III

440

Industry-led

1,137

With posted results

1,241

Countries with sites

91

Published source: clinicaltrials · first_posted_date as posted